Beckman Coulter Diagnostics recently announced the addition of assays such as 6-Acetylmorphine (6-AM) and Buprenorphine (BUP) to its broad menu of drugs-of-abuse tests that serve the needs of onsite testing laboratories.
With the rise in drug abuse and opioid usage, the demand for effective test assays is also increasing. Beckman Coulter Diagnostics is an experienced manufacturer of scalable instruments and comprehensive diagnostic tests which help healthcare and laboratory professionals to provide better patient care by delivering the accurate diagnostic information they need. The company’s newly added convenient and easy-to-use assays for drug-of-abuse screenings are the Syva Emit II Plus 6-AM and Syva Emit II Plus BUP. They offer fast, accurate and reliable drugs-of-abuse screening and will be accessible to clinical laboratories that are using Beckman Coulter’s scalable AU chemistry analyzer solutions (AU480/AU680/AU5800). Combining AU analyzers with these assays will provide fast, accurate and reliable drugs-of-abuse screenings.
Syva® EMIT II Plus 6-AM
- An alternative to time-consuming methods like gas chromatography and mass spectrometry (GC/MS), this assay provides a convenient and quick way to selectively screen for heroin usage.
- It also minimizes false positives by demonstrating no cross-reactivity to morphine, morphine metabolites and common analgesics.
Syva® EMIT® II Plus BUP
- Intended for use in laboratories for the qualitative and/or semi-quantitative analysis of buprenorphine in human urine, this assay also minimizes false positives due to its high specificity for buprenorphine and norbuprenorphine, with no cross-reactivity to commonly abused opiates.
- With a low cutoff of 5 ng/mL, the BUP assay performs with improved sensitivity to minimize false negative results.
Clinical laboratories gain greater confidence in opioid testing with the proven high-specificity and high-sensitivity of the Syva® EMIT® II Plus 6-AM and BUP assays. Both assays deliver greater than 99% agreement with the reference method and enable accurate interpretation of results.
In a press release, Michael Samoszuk, M.D., chief medical officer, Beckman Coulter Diagnostics, said, “Overdose with amphetamines requires a different treatment than opioid-related overdose. Therefore, providing hospitals and clinical laboratories with highly specific tests to distinguish between these two classes of drugs is important to ensure that patients receive appropriate care,”